Jonathan Foley
Executive Director, COO & Co-Founder
Jonathan is a Scientific Director at Argobio.
Jonathan Foley is Scientific Director at Argobio with 20 years of experience in drug discovery, analytical development, and rare disease research. Most recently, Jonathan was the Head of Discovery at Freeline Therapeutics (now Spur Therapeutics) Prior to Freeline, he was a Lecturer at University College London in the group of gene therapy pioneer Professor Amit Nathwani and was a member of the first research team that spun Freeline out of academia. During his academic career he published extensively in the areas of biochemistry, bleeding disorders and complement-mediated disease. Jonathan holds a PhD in Biochemisty from Queen’s University, Canada and held a prestigious Banting Fellowship at the University of British Columbia.
Jonathan Foley is Scientific Director at Argobio with 20 years of experience in drug discovery, analytical development, and rare disease research. Most recently, Jonathan was the Head of Discovery at Freeline Therapeutics (now Spur Therapeutics) Prior to Freeline, he was a Lecturer at University College London in the group of gene therapy pioneer Professor Amit Nathwani and was a member of the first research team that spun Freeline out of academia. During his academic career he published extensively in the areas of biochemistry, bleeding disorders and complement-mediated disease. Jonathan holds a PhD in Biochemisty from Queen’s University, Canada and held a prestigious Banting Fellowship at the University of British Columbia.
